Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theratechnologies Inc (TSE:TH)
TSX:TH
TH Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.59 - C$3.13
Previous CloseN/A
Volume38.24K
Average Volume (3M)46.88K
Market Cap
$125.07M
Enterprise ValueC$110.99M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Feb 26, 2025EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding45,980,020
10 Day Avg. Volume74,962
30 Day Avg. Volume46,885
Standard Deviation0.28
R-Squared0.06
Alpha-0.00625
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.04
Price to Cash Flow (P/CF)4.80
P/FCF Ratio3.40
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.79
Enterprise Value/Ebitda9.16
Forecast
1Y Price Target
C$3.80Price Target Upside42.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Theratechnologies News
PremiumCompany Announcements
Theratechnologies Resumes EGRIFTA SV® Distribution Following FDA Clearance
PremiumCompany Announcements
Theratechnologies Seeks FDA Approval for Manufacturing Changes to EGRIFTA SV®
PremiumCompany Announcements
Theratechnologies Seeks FDA Approval for EGRIFTA SV® Changes
---
Bulls Say, Bears Say
Bulls Say
Financial Performance2Q24 total revenue of $22M from sales of EGRIFTA SV and TROGARZO exceeded our estimate of $19.52M and consensus of $21.73M.
ProfitabilityTHTX reports a positive net income for the first time, marking the beginning of sustainable profitability for the company.
Revenue GrowthEGRIFTA SV remains the key revenue driver, demonstrating a 26.6% year-over-year increase.
Bears Say
Competitive PressuresTROGARZO sales decreased 22.9% year-over-year due to a loss of market share secondary to competitive pressures.
Operational ChallengesThe stock is facing near-term headwinds until the full impact of the manufacturing pause on the key revenue driving asset EGRIFTA SV is confirmed.
Supply Chain RisksThere is a risk of a temporary supply disruption for EGRIFTA SV due to an unexpected voluntary shutdown of the contract manufacturer's facility following an FDA inspection.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.06% Mutual Funds
23.44% Other Institutional Investors
76.51% Public Companies and Individual Investors
TH FAQ
What was Theratechnologies Inc’s price range in the past 12 months?
Theratechnologies Inc lowest stock price was C$1.59 and its highest was C$3.13 in the past 12 months.
What is Theratechnologies Inc’s market cap?
Theratechnologies Inc’s market cap is $125.07M.
When is Theratechnologies Inc’s upcoming earnings report date?
Theratechnologies Inc’s upcoming earnings report date is Feb 26, 2025 which is in 5 days.
How were Theratechnologies Inc’s earnings last quarter?
Theratechnologies Inc released its earnings results on Oct 10, 2024. The company reported C$0.085 earnings per share for the quarter, beating the consensus estimate of C$0.043 by C$0.043.
Is Theratechnologies Inc overvalued?
According to Wall Street analysts Theratechnologies Inc’s price is currently Undervalued.
Does Theratechnologies Inc pay dividends?
Theratechnologies Inc does not currently pay dividends.
What is Theratechnologies Inc’s EPS estimate?
Theratechnologies Inc’s EPS estimate is 0.07.
How many shares outstanding does Theratechnologies Inc have?
Theratechnologies Inc has 45,980,020 shares outstanding.
What happened to Theratechnologies Inc’s price movement after its last earnings report?
Theratechnologies Inc reported an EPS of C$0.085 in its last earnings report, beating expectations of C$0.043. Following the earnings report the stock price went up 4.79%.
Which hedge fund is a major shareholder of Theratechnologies Inc?
Currently, no hedge funds are holding shares in TSE:TH
---
Theratechnologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$3.80 (42.86% Upside)
C$3.80 (42.86% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 10.9%
Last 30 Days ▼ 10.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.98%
Trailing 12-Months
Company Description
Theratechnologies Inc
Theratechnologies, Inc. is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies was founded on October 19, 1993 and is headquartered in Montreal, Canada.
---
TH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive financial performance and growth for EGRIFTA SV, alongside challenges related to supply chain issues and declining sales for Trogarzo. Despite the supply disruptions, the company remains optimistic about its profitability and strategic direction.Read More>---
TH Stock 12 Month Forecast
Average Price Target
C$3.80
▲(42.86% Upside)
Technical Analysis
Oncolytics Biotech
―
Bausch Health Companies
―
Neo Performance Materials Inc
―
HLS Therapeutics Inc
―
Premier Health of America Inc
―
Best Analysts Covering TH
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
+4.45%
reiterated a buy rating 7 days ago
Copying Andre Uddin's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +4.45% per trade.
---